Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Delivery of RNAi mediators.

Ford LP, Toloue MM.

Wiley Interdiscip Rev RNA. 2010 Sep-Oct;1(2):341-50. doi: 10.1002/wrna.12. Epub 2010 Jun 3. Review.

PMID:
21935894
2.

Antibody targeted siRNA delivery.

Toloue MM, Ford LP.

Methods Mol Biol. 2011;764:123-39. doi: 10.1007/978-1-61779-188-8_8.

PMID:
21748637
3.

A step-by-step procedure to analyze the efficacy of siRNA using real-time PCR.

Cheng A, Johnson CL, Ford LP.

Methods Mol Biol. 2008;419:303-16. doi: 10.1007/978-1-59745-033-1_21.

PMID:
18369992
4.

Using synthetic precursor and inhibitor miRNAs to understand miRNA function.

Ford LP, Cheng A.

Methods Mol Biol. 2008;419:289-301. doi: 10.1007/978-1-59745-033-1_20.

PMID:
18369991
5.

Applying small RNA molecules to the directed treatment of human diseases: realizing the potential.

Pappas TC, Bader AG, Andruss BF, Brown D, Ford LP.

Expert Opin Ther Targets. 2008 Jan;12(1):115-27. Review.

PMID:
18076375
6.

Role of miRNA and miRNA processing factors in development and disease.

Conrad R, Barrier M, Ford LP.

Birth Defects Res C Embryo Today. 2006 Jun;78(2):107-17. Review.

PMID:
16847880
7.

Using synthetic miRNA mimics for diverting cell fate: a possibility of miRNA-based therapeutics?

Ford LP.

Leuk Res. 2006 May;30(5):511-3. Epub 2005 Oct 20. No abstract available.

PMID:
16242778
9.

Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis.

Cheng AM, Byrom MW, Shelton J, Ford LP.

Nucleic Acids Res. 2005 Mar 1;33(4):1290-7. Print 2005.

10.

BCR/ABL activates mdm2 mRNA translation via the La antigen.

Trotta R, Vignudelli T, Candini O, Intine RV, Pecorari L, Guerzoni C, Santilli G, Byrom MW, Goldoni S, Ford LP, Caligiuri MA, Maraia RJ, Perrotti D, Calabretta B.

Cancer Cell. 2003 Feb;3(2):145-60.

11.

Human Ku70/80 associates physically with telomerase through interaction with hTERT.

Chai W, Ford LP, Lenertz L, Wright WE, Shay JW.

J Biol Chem. 2002 Dec 6;277(49):47242-7. Epub 2002 Oct 10.

12.

c-Myc controls proliferation versus differentiation in human pancreatic endocrine cells.

Demeterco C, Itkin-Ansari P, Tyrberg B, Ford LP, Jarvis RA, Levine F.

J Clin Endocrinol Metab. 2002 Jul;87(7):3475-85.

PMID:
12107268
13.

A model for heterogeneous nuclear ribonucleoproteins in telomere and telomerase regulation.

Ford LP, Wright WE, Shay JW.

Oncogene. 2002 Jan 21;21(4):580-3. Review.

14.

An in vitro assay to study regulated mRNA stability.

Fritz DT, Ford LP, Wilusz J.

Sci STKE. 2000 Dec 5;2000(61):pl1.

PMID:
11752625
15.
16.

Telomerase can inhibit the recombination-based pathway of telomere maintenance in human cells.

Ford LP, Zou Y, Pongracz K, Gryaznov SM, Shay JW, Wright WE.

J Biol Chem. 2001 Aug 24;276(34):32198-203. Epub 2001 Jun 6.

17.

Heterogeneous nuclear ribonucleoproteins C1 and C2 associate with the RNA component of human telomerase.

Ford LP, Suh JM, Wright WE, Shay JW.

Mol Cell Biol. 2000 Dec;20(23):9084-91.

18.
19.

Two inactive fragments of the integral RNA cooperate to assemble active telomerase with the human protein catalytic subunit (hTERT) in vitro.

Tesmer VM, Ford LP, Holt SE, Frank BC, Yi X, Aisner DL, Ouellette M, Shay JW, Wright WE.

Mol Cell Biol. 1999 Sep;19(9):6207-16.

20.
21.
22.
23.
25.

Evaluating productivity in clinical research programs: the National Cancer Institute's (NCI) Community Clinical Oncology Program (CCOP).

Hynes DM, McLaughlin CP, Kaluzny AD, Ford LP, Sondik E.

J Med Syst. 1992 Dec;16(6):247-67.

PMID:
1304594

Supplemental Content

Support Center